zelenirstat

[rgs1204]

Has anybody heard of this drug? I just read about it today, and I'm wondering if it might be effective for Richters at some point.

globalnews.ca/news/11014594...

pmc.ncbi.nlm.nih.gov/articl...

[SofiaDeo]

We'll see if this drug that seems to work in a test tube, actually works in humans. Since something like mmm 90%? of cancer drugs fail the approval process before coming to market, I am cautiously optimistic.

pmc.ncbi.nlm.nih.gov/articl...

With newer technology identifying major metabolic processes of various cancers, and their molecular structures/interactions, hopefully in the upcoming decades the 90% failure rate changes for the better.

[rgs1204 in reply to SofiaDeo]

I know what you mean. I think every food or supplement known has been found to kill CLL cells in vitro, but not so much in vivo.

This study does refer to an early trial using 29 actual humans though, and had enough meat to warrant "the US FDA has granted IND approval, fast-track and orphan drug designations for the development of zelenirstat in relapsed adult AML"

This seems promising at least, and I was just wondering if the diffuse B cell Lymphoma they are talking about is the same type that we might be affected with from CLL.

I'll take any good news that's out there, and I'm thankful every day for the work that's been put in to get us where we are today.

[AussieNeil Partner Administrator]

Given "The cancer with the highest sensitivity scores included diffuse large B-cell lymphoma (DLBCL), AML, testicular germ cell tumors, squamous cell carcinoma of the lung, colorectal carcinomas, basal subtype breast cancers, and ovarian carcinoma." and

"However, profound tumor regression and complete remissions were seen in patient derived xenograft models of refractory DLBCL, where loss of Src-Lyn and human germinal center-associated lymphoma (HGAL) proteins, which require myristylation to function, inhibited B-cell receptor survival signaling [5]. "

I hope you are right about zelenirstat. They have enrolled 3 DLBCL patients in their phase 1 clinical trial, so we should get some idea soon.

Neil